Effıcıency of Sexual and Reproductıve Health Educatıon

NCT05864430 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2023-05-18

No results posted yet for this study

Summary

The youth period is a period when information and education are important. Reproductive and sexual health problems have an important place in aging health problems in youth (Gölbaşlı 2003). All over the world, STIs are most common in the 20-24 age group, followed by the 15-19 and 25-29 age groups. STIs are the most common disease in many countries, especially among young people between the ages of 15-29 (Topbaş et al. 2003). STIs, which are one of the factors that negatively affect public health; are infections transmitted from person to person through sexual contact. According to WHO estimates, approximately 350 million people suffer from curable STIs each year, and the incidence and prevalence of STIs among young people in developed and developing countries are increasing.

Although young adults are generally at risk, STIs are most common in people aged 15-49. They have a very important place in terms of human health because they are frequently seen, difficult to diagnose, and cause serious complications when not treated. Incomplete and incorrect information among people who start sexual intercourse at an early age causes difficulties in the prevention of these diseases (Özalp et al. 2012).

Having sexual intercourse at an early age, being polygamous, having special sexual preferences, being with or having sex with those who have paid for sexual intercourse, and not using condoms are among the risk factors for STIs (Siyez 2009).

We can say that the age period in which STIs are common is parallel to sexual activity. In addition to various socio-demographic factors, it is likely that the most provoking issue in this period is the lack of knowledge of young people (Karaköse and Aydın 2011).

In the STD guide published by the CDC, it is recommended to evaluate the people who constitute the risk group in the prevention of these diseases and to provide education and counseling (CDC, 2020). In this context, training to increase the level of knowledge and awareness of young people, who are one of the high-risk groups in society in terms of STD, is important in terms of reducing risky sexual behaviors, early diagnosis, and treatment.

Based on all these reasons; It is aimed to evaluate the effectiveness of sexual and reproductive health education given to university students.

Conditions

  • Reproductive Health
  • Sexual Health

Interventions

OTHER

Face-to-face Training Group

The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.

OTHER

DataMatrix supported Face-to-face training group

Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.

OTHER

Online training group

The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.

Sponsors & Collaborators

  • Marmara University

    lead OTHER

Principal Investigators

  • Tuğba Öz · ev

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-15
Primary Completion
2022-09-30
Completion
2022-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05864430 on ClinicalTrials.gov